Trial Profile
An open-label study to determine the efficacy and safety of STI571 [imatinib] in patients with chronic myeloid leukemia in blast crisis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 25 Sep 2005 New trial record.